Division of Hematology and Oncology

A new mouse model demonstrates that the Hhex gene – which is linked to blood cancers – is critical for normal blood cell production.

Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators.

A group of Vanderbilt-led investigators has identified a new gene mutation that may explain why some breast cancer patients do not respond to anti-hormone therapy.

The grants, which total $830,000, are part of the non-profit organization’s commitment to young scientists, as well as established investigators who are searching for more effective breast cancer therapies.

A Vanderbilt lung cancer patient’s exceptional response to different types of therapies spurred research that suggests lung cancer patients with specific gene alterations may benefit from combination therapy that targets two different cancer pathways.

Two Vanderbilt-Ingram Cancer Center investigators have received multi-year breast cancer research grants from the Susan G. Komen for the Cure Breast Cancer Foundation.

The LUNGevity Foundation has awarded a 2014 Career Development Award for Translational Research to Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology.